Neurochem CEO: Odds Of Kiacta Approval 'Much Higher' - Forbes.com

Neurochem CEO: Odds Of Kiacta Approval 'Much Higher': "Neurochem's late-stage drug candidate Alzhemed remains the main focus for investors. Preliminary Phase III trial data for the experimental Alzheimer's disease treatment is expected in the second quarter of 2007.
'At a current market cap of $366 million, we believe the Street is only giving Alzhemed a one-in-four probability of approval,' said CIBC's Lian. 'We believe the drug is disproportionately discounted at these levels.'"